BR112015019126A2 - Vacina de combinação para vírus sincicial respiratório e influenza - Google Patents

Vacina de combinação para vírus sincicial respiratório e influenza

Info

Publication number
BR112015019126A2
BR112015019126A2 BR112015019126A BR112015019126A BR112015019126A2 BR 112015019126 A2 BR112015019126 A2 BR 112015019126A2 BR 112015019126 A BR112015019126 A BR 112015019126A BR 112015019126 A BR112015019126 A BR 112015019126A BR 112015019126 A2 BR112015019126 A2 BR 112015019126A2
Authority
BR
Brazil
Prior art keywords
influenza
respiratory syncytial
combination
syncytial virus
combination vaccine
Prior art date
Application number
BR112015019126A
Other languages
English (en)
Inventor
E Smith Gale
Glenn Greg
Fries Lou
F Young James
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BR112015019126A2 publication Critical patent/BR112015019126A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VACINA DE COMBINAÇÃO PARA VÍRUS SINCICIAL RESPIRATÓRIO E INFLUENZA. A presente divulgação é dirigida às composições e métodos para aumentar respostas imunes contra vírus influenza e sincicial respiratório através da administração da composição imunogênica de combinação contra os vírus ao mesmo tempo. As composições de combinação contêm um componente de RSV e um, dois, três, quatro ou mais componentes de influenza. As composições de combinação fornecem uma resposta imune maior do que aquelas obtidas pela administração separada dos componentes de RSV e influenza.
BR112015019126A 2013-02-11 2014-02-11 Vacina de combinação para vírus sincicial respiratório e influenza BR112015019126A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763309P 2013-02-11 2013-02-11
US201361875327P 2013-09-09 2013-09-09
PCT/US2014/015725 WO2014124423A1 (en) 2013-02-11 2014-02-11 Combination vaccine for respiratory syncytial virus and influenza

Publications (1)

Publication Number Publication Date
BR112015019126A2 true BR112015019126A2 (pt) 2017-08-22

Family

ID=50185053

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019126A BR112015019126A2 (pt) 2013-02-11 2014-02-11 Vacina de combinação para vírus sincicial respiratório e influenza

Country Status (13)

Country Link
US (1) US20140227309A1 (pt)
EP (1) EP2953642A1 (pt)
JP (1) JP2016509015A (pt)
KR (1) KR20150138184A (pt)
CN (1) CN105101992A (pt)
AU (1) AU2014214590A1 (pt)
BR (1) BR112015019126A2 (pt)
CA (1) CA2900489A1 (pt)
IL (1) IL240504A0 (pt)
MX (1) MX2015010305A (pt)
RU (1) RU2015138530A (pt)
SG (1) SG11201506197TA (pt)
WO (1) WO2014124423A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
HUE051666T2 (hu) 2008-12-09 2021-03-29 Novavax Inc Módosított RSV F fehérjék és alkalmazásuk módszerei
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
JP6764408B2 (ja) 2014-12-19 2020-09-30 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与
CN114796474A (zh) 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
CN106822887A (zh) * 2017-01-26 2017-06-13 中国科学院微生物研究所 一种流感病毒四价亚单位疫苗及其应用
CN107961371B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 季节流感-rsv联合疫苗及其制备方法和应用
AU2019238171A1 (en) 2018-03-19 2020-09-24 Novavax, Inc. Multivalent influenza nanoparticle vaccines
CN110559434B (zh) * 2018-06-05 2022-08-19 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
WO2024089634A1 (en) * 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01006214A (es) * 1998-12-17 2004-09-06 Aventis Pasteur Composicion inmunogenica multivalente que contiene una preparacion de virus de influenza y una composicion de subunidad del virus sincicial respiratorio.
EP2181121A4 (en) * 2007-03-21 2012-07-11 Id Biomedical Corp Quebec CHIMÄRE ANTIGENE
JP2010533737A (ja) * 2007-07-19 2010-10-28 ノババックス，インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
HUE051666T2 (hu) * 2008-12-09 2021-03-29 Novavax Inc Módosított RSV F fehérjék és alkalmazásuk módszerei

Also Published As

Publication number Publication date
EP2953642A1 (en) 2015-12-16
AU2014214590A1 (en) 2015-08-27
KR20150138184A (ko) 2015-12-09
JP2016509015A (ja) 2016-03-24
SG11201506197TA (en) 2015-09-29
MX2015010305A (es) 2015-11-18
RU2015138530A (ru) 2017-03-20
CA2900489A1 (en) 2014-08-14
CN105101992A (zh) 2015-11-25
US20140227309A1 (en) 2014-08-14
IL240504A0 (en) 2015-09-24
WO2014124423A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
BR112015019126A2 (pt) Vacina de combinação para vírus sincicial respiratório e influenza
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112018007876A2 (pt) derivado de benzofurano, método de preparação do mesmo e uso do mesmo na medicina
BR112017018022A2 (pt) "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112018013218A2 (pt) derivado de acrilanilida, método de preparação e aplicação do mesmo na farmácia
BR112017025499A2 (pt) benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa
BR112015014753A2 (pt) composições, utilização de uma composição, método para o combate dos fungos fitopatogênicos e semente
BR112015023142A2 (pt) moduladores de p2x7
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
BR112015007183A2 (pt) composições, uso de uma composição, método para o combate dos fungos e semente
BR112015015758B8 (pt) Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida
BR112014013661A2 (pt) Derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
BR112017000519A2 (pt) "composição imunogênica, e, método para proteger um mamífero contra uma infecção meningocócica"
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]